This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Next Week's Game Plan

Finally, when asked about moving toward a more cloud-based payroll service, Mucci said Paychex already has a software-as-a-service model, but also combines that with a dedicated payroll specialist to assist with any questions. He said that, ultimately, many companies will move their payroll functions to a cloud-based model, but Paychex remains a strong believer in also providing the specialists.

Cramer reiterated his buy on Paychex, saying the dividend pays investors to wait until hiring returns, at which time Paychex will be one stock headed to the moon.

A Healthy Regeneron

Inventing new drugs is still a great growth business, Cramer told viewers, but that business has moved away from the big pharma names of old and into a new generation of biotech companies including Regeneron (REGN), a stock Cramer has touted for eight years for a gain of 3,400%.

Cramer said that despite the staggering growth over the past eight years, Regeneron is still a value stock -- it trades at just 30 times earnings despite a 29% annual growth rate. He said investors shouldn't let the stock's high share price deter them because this is one stock that still has plenty of room to grow.

Regeneron's main product is Eylea, a best-in-class treatment for macular degeneration. The drug only requires half as many injections as its rivals and has been a huge hit with doctors and patients. But Regeneron isn't stopping there. The company has several new indications that Eylea could possibly treat, and it is hard at work exploring all of them.

Beyond Eylea, there's also Regeneron's bowel cancer treatment, which only accounted for $31 million in sales for 2012 but is growing and just received approval in Europe. Regeneron is also working on anti-inflammatory drugs as well as anti-cholesterol, arthritis, dermatitis and asthma treatments.

With all of these great opportunities in the works, Cramer said Regeneron is still on of his favorite biotech names.

Lightning Round

In the Lightning Round, Cramer was bullish on Sunoco Logistics Partners (SXL), MarkWest Energy Partners (MWE), Nucor (NUE), Verizon (VZ), CVR Energy (CVI), Millennial Media (MM) and Anheuser-Busch InBev (BUD).

Hassan's Playbook

In a special interview, Cramer sat down with Fred Hassan, former CEO of Schering-Plough and the author of "Reinvent: A Leader's Playbook for Serial Success."

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,952.71 +33.12 0.20%
S&P 500 1,983.51 +1.91 0.10%
NASDAQ 4,529.5610 +2.0470 0.05%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs